---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-105240"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2026-09-30T20:15:18+00:00"
generated_at: "2026-10-12T14:05:21.959078+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MoonLake files FDA BLA for sonelokimab in hidradenitis suppurativa

## Summary
- BLA submitted September 30, 2026 seeking approval of tri-specific nanobody sonelokimab for moderate-to-severe hidradenitis suppurativa in adults and pediatric patients 12 and older.
- MoonLake expects FDA notice on whether the BLA is accepted for review within roughly 60 days of submission, and the planned review timeline within roughly 74 days.
- Filing discloses no efficacy, safety, pricing or financial data; the 8-K reports only the regulatory submission milestone.
- Risks cited include limited operating history, difficulty enrolling patients in clinical trials, and reliance on third parties for trials; signed by CFO Matthias Bodenstedt.

## SEC filing metadata
- accession: 0001213900-26-105240
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2026-09-30T20:15:18+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390026105240/0001213900-26-105240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390026105240/ea0307097-8k_moonlake.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-105240
- JSON: https://secwatch.observer/filing/0001213900-26-105240.json
- Plain text: https://secwatch.observer/filing/0001213900-26-105240.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.